Nanexa AB (NANEXA) - Total Liabilities
Based on the latest financial reports, Nanexa AB (NANEXA) has total liabilities worth Skr39.57 Million SEK (≈ $4.26 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nanexa AB - Total Liabilities Trend (2014–2025)
This chart illustrates how Nanexa AB's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Nanexa AB to evaluate short-term liquidity relative to the company's equity base.
Nanexa AB Competitors by Total Liabilities
The table below lists competitors of Nanexa AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Global Data Centre Group
AU:GDC
|
Australia | AU$27.86 Million |
|
IBU tec advanced materials AG
XETRA:IBU
|
Germany | €16.58 Million |
|
GIIR Inc
KO:035000
|
Korea | ₩282.88 Billion |
|
Superior Plating Technology Co Ltd
TWO:8431
|
Taiwan | NT$455.57 Million |
|
PolyPid
NASDAQ:PYPD
|
USA | $11.33 Million |
|
Globrands Group Ltd
TA:GLRS
|
Israel | ILA570.15 Million |
|
Koryo Electronics Co Ltd
TWO:8032
|
Taiwan | NT$1.25 Billion |
|
Nasmedia Co. Ltd
KQ:089600
|
Korea | ₩185.10 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Nanexa AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nanexa AB market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanexa AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanexa AB (2014–2025)
The table below shows the annual total liabilities of Nanexa AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr36.61 Million ≈ $3.94 Million |
+75.21% |
| 2024-12-31 | Skr20.90 Million ≈ $2.25 Million |
-42.64% |
| 2023-12-31 | Skr36.43 Million ≈ $3.92 Million |
-40.38% |
| 2022-12-31 | Skr61.10 Million ≈ $6.58 Million |
+345.88% |
| 2021-12-31 | Skr13.70 Million ≈ $1.47 Million |
+32.52% |
| 2020-12-31 | Skr10.34 Million ≈ $1.11 Million |
-2.08% |
| 2019-12-31 | Skr10.56 Million ≈ $1.14 Million |
-9.05% |
| 2018-12-31 | Skr11.61 Million ≈ $1.25 Million |
+103.42% |
| 2017-12-31 | Skr5.71 Million ≈ $614.26K |
+57.47% |
| 2016-12-31 | Skr3.62 Million ≈ $390.09K |
+109.73% |
| 2015-12-31 | Skr1.73 Million ≈ $185.99K |
+54.67% |
| 2014-12-31 | Skr1.12 Million ≈ $120.25K |
-- |
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more